SCHEMBL3830596

SCHEMBL3830596

CC(C)[Si](Oc1cccc2oc3ccccc3c12)(C(C)C)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 5/20 0.46
▸ ADRB2 P07550 1/20 0.44
▸ KDM4E B2RXH2 4/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HPGD P15428 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GLA P06280 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ PGAM1 P18669 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31533293 0.84 KMT2A (0.37) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL31336207 0.82 ABCG2 (0.37) MAOAKDM4EALDH1A1NPC1LMNA
SCHEMBL5026754 0.75 MAOA (0.74) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL10431693 0.72 ADRB2 (0.48) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL6002951 0.72 MAOA (0.50) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL17076945 0.72 PGR (0.39) MAOAKDM4EALDH1A1NPC1LMNA
SCHEMBL13990695 0.71 CYP2A6 (0.57) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL1926672 0.71 MAOA (0.47) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL2685825 0.70 MAOA (0.49) MAOAADRB2KDM4EALDH1A1NPC1
SCHEMBL15473271 0.69 CYP2A6 (0.59) MAOAADRB2KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1755585-A4 TRANSTHYRETIN STABILIZATION SCRIPPS RESEARCH INST (US) 2009-04-01 — — EP disclosed
US-20080319175-A1 Transthyretin Stabilization THE SCRIPPS RESEARCH INSTITUTE (US) 2008-12-25 — — US disclosed
EP-1755585-A1 TRANSTHYRETIN STABILIZATION The Scripps Research Institute (US) 2007-02-28 — — EP disclosed
WO-2005112913-A1 TRANSTHYRETIN STABILIZATION THE SCRIPPS RESEARCH INSTITUTE (US) 2005-12-01 — — WO disclosed
US-20050261365-A1 Transthyretin stabilization THE SCRIPPS RESEARCH INSTITUTE (US) 2005-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261365-A1 Transthyretin stabilization TTR, TTPA, ALB MAOA 1813/4885ADRB2 4226/4885KDM4E 3239/4885
US-20080319175-A1 Transthyretin Stabilization TTR, TTPA, ALB MAOA 1813/4885ADRB2 4226/4885KDM4E 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback